Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.36 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7679792 | 0.72 | TDP1 (0.47) | TDP1MEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL28601469 | 0.72 | CHEK1 (0.36) | TDP1ALDH1A1CYP3A4HSD17B10KDM4E | |
| SCHEMBL29655073 | 0.69 | MGAM (0.48) | TDP1MEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL16738874 | 0.64 | ALOX5AP (0.48) | TDP1ALDH1A1CYP3A4TSHRHSD17B10 | |
| SCHEMBL29655181 | 0.64 | CYP3A4 (0.64) | TDP1MEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL416690 | 0.63 | TDP1 (0.52) | TDP1MEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL5953394 | 0.63 | PTPRC (0.56) | TDP1MEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL29655234 | 0.63 | PTPRC (0.56) | TDP1MEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL29655117 | 0.63 | PTPRC (0.56) | TDP1MEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL7679791 | 0.63 | ALDH1A1 (0.47) | TDP1MEN1KMT2AALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6441198-B1 | USEFUL AS ANTITUMOUR AGENTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2002-08-27 | — | — | US | claimed |
| US-20020082432-A1 | New podophyllotoxin dimer as DNA topoisomerase II inhibitors, and a process for the preparation therefore | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2002-06-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082432-A1 | New podophyllotoxin dimer as DNA topoisomerase II inhibitors, and a process for the preparation therefore | TOP2A, TOP2B, PCNA | TDP1 65/4885MEN1 4424/4885KMT2A 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.